Revvity, 3029-0010, Neonatal Total Galactose kit (10 plate)

Overview
The Neonatal Total Galactose kit is designed for the quantitative determination of total galactose (galactose and galactose-1-phosphate) concentrations in dried blood spot specimens from newborns. This assay provides laboratories with a reliable and efficient solution to support newborn screening programs for galactosemia, a rare but potentially life-threatening metabolic disorder.
Why screen for total galactose?
Galactosemia is caused by an inherited enzyme deficiency that prevents the body from properly metabolizing galactose, a sugar found in milk and many other foods. Without early diagnosis and dietary management, affected newborns are at risk of severe complications, including liver damage, sepsis, and developmental delays. Measuring both galactose and galactose-1-phosphate in dried blood spots provides a sensitive and effective means of detecting infants at risk, ensuring they can receive timely intervention.
Accurate and reliable measurement
The Neonatal Total Galactose kit is specifically designed for use in high-throughput newborn screening laboratories. The assay offers:

Accurate quantification of total galactose, combining galactose and galactose-1-phosphate measurements.
Robust and reproducible performance to support population-scale screening.
Compatibility with dried blood spot samples, the standard format for neonatal testing.

Efficiency for laboratory workflows
With a 10-plate format, the kit provides laboratories with the capacity to process large volumes of samples efficiently. Its design supports streamlined workflows while maintaining the precision and consistency required in national and regional newborn screening programs. This balance of throughput and reliability allows laboratories to confidently meet increasing demands.
A trusted choice for newborn screening
The Neonatal Total Galactose kit reflects a longstanding commitment to providing validated, high-quality solutions that support public health goals. By enabling the early identification of galactosemia, it empowers healthcare providers to deliver timely care and protect the health of newborns. Application-Newborn Screening
Brand-NeoBase™
Detection Modality-Enzymatic
Disorders-Galactosemia
Instrument Compatibility-Victor 2D
Quantity-960 tests
Regulatory Status-CE-IVD marked
Sample Type-Dried blood spots
Technology-Enzymatic
Unit Size-10 plates